KOL KnockoutTM: Retina Edition – Treatment Outcomes to Vie F -

KOL Knockout Retina Edition Treatment Outcomes to Vie For Round 3

Media formats available:

Details

Presenters

Overview
Round 3 of this exciting CME program will be hosted by Program Chair Sunil K. Srivastava, MD, and will feature contestants Ajay E. Kuriyan, MD, MS; Yasha Modi, MD (Round 2 winner); and Jayanth Sridhar, MD.
The program includes patient case studies with each KOL weighing in on the treatment options. The audience will vote on the final winner!
There will be learning, laughter, and only one KOL left standing!

This activity is supported by independent educational grants from Bausch + Lomb and Genentech, a member of the Roche Group.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Recognize the barriers to early diagnosis and intervention for patients with retinal disease
- Evaluate key data from clinical studies to determine the medical and surgical treatment approaches that would be most effective in managing disease presentation in real-world settings
- Describe the role of visualization in common vitreoretinal surgical procedure
- Formulate troubleshooting guides to mitigate the effect of unexpected intraoperative vitreous behavior
- Develop algorithms to identify and surgically treat patients who may benefit from cutting-edge durable therapies for the treatment of diabetic eye diseases and neovascular age-related macular degeneration
Accreditation
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement[s] for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Sunil K. Srivastava, MD
Surgical Retina Fellowship Director
Cleveland Clinic Cole Eye Institute
Cleveland, OH

Ajay E. Kuriyan, MD, MS
Wills Eye Physicians
Mid Atlantic Retina
Associate Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA

Yasha S. Modi, MD
Associate Professor of Ophthalmology
Department of Ophthalmology
Director of Tele-Retina NYU Langone Health
New York, NY

Jayanth Sridhar, MD
Associate Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute
Miami, FL

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Sunil K. Srivastava, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biotechnologies, Allergan, Bausch + Lomb, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Eyevensys, jCyte, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Bausch + Lomb, EyePoint Pharmaceuticals, Eyevensys, jCyte, Novartis, and Regeneron Pharmaceuticals.
Ajay E. Kuriyan, MD, MS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan, Bausch + Lomb, Eyepoint Pharmaceuticals, Optos, Novartis, Genentech/Roche, Recens Medical, and Spark Therapeutics. Grant/Research Support: Alcon Research Institute Young Investigator Award; Adverum, Annexon, and Genentech/Roche. Speakers Bureau: Alimera Sciences, Allergan, Bausch + Lomb, Eyepoint Pharmaceuticals, Optos, Novartis, Genentech/Roche, Recens Medical, and Spark Therapeutics. Shareholder: Recens Medical.
Yasha S. Modi, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan/AbbVie, Carl Zeiss Meditec, DORC, Genentech, Iveric Bio, and Théa Pharma.
Jayanth Sridhar, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Apellis Pharmaceuticals, DORC, Genentech, OcuTerra, and Regeneron.
The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Bausch + Lomb, or Genentech, a member of the Roche Group.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/09/2022
Expiration Date: 12/23/2022